Lantern Pharma Uses AI to Transform Cancer Drug Development | Breakthrough Trials & ZETA Platform

For biotech investors, medical innovators, and AI technology leaders — this New to The Street interview from the New York Stock Exchange features Lantern Pharma’s President & CEO, detailing how the company is using artificial intelligence to radically accelerate cancer drug discovery and development.

In 2025 alone, Lantern Pharma dosed nearly 100 patients across multiple clinical trials, achieving complete metabolic responses, meaningful survival extensions in ultra-rare cancers, and international trial expansion into Japan and Taiwan. By applying AI to early-stage R&D, Lantern has compressed drug development timelines from years to months — often at less than one-tenth the traditional cost.

A major highlight is the upcoming launch of ZETA, Lantern’s next-generation AI platform designed to analyze billions of genomic, chemical, and clinical data points through natural language interaction. The platform enables rapid development of targeted therapies for over 439 rare cancers, an area that accounts for a quarter of cancer deaths but remains chronically under-served.

Looking ahead to 2026, Lantern is advancing multiple FDA-cleared trials in bladder cancer, lung cancer, triple-negative breast cancer, and brain cancer through its upcoming Starlight Therapeutics spin-out. With strong regulatory designations and a mission to democratize AI-powered drug development, Lantern Pharma is positioning itself at the forefront of what it calls a new golden age in medicine.

#NewToTheStreet #LanternPharma #AIDrugDiscovery #CancerResearch #BiotechInnovation #ClinicalTrials #RareCancers #Oncology #ArtificialIntelligence #PrecisionMedicine #DrugDevelopment #ZETAPlatform #AntibodyDrugConjugates #FDAFastTrack #BiotechStocks #HealthcareInnovation #MedicalBreakthrough #InvestorInsights #NYSE #FintechTV